武汉武药制药有限公司

About 武汉武药制药有限公司

Wuhan Wuyao Pharmaceutical Co., Ltd. is a holding subsidiary invested in and established by Grand Pharma (China) Co., Ltd. (formerly Wuhan Pharmaceutical Factory) in 2002. It is a well-known enterprise in China specializing in the production and operation of characteristic APIs. The company passed the "Safety Production Standardization Level II Enterprise" acceptance; in the same year, it was rated as a "High-tech Enterprise" in Hubei Province. Wuhan Wuyao Pharmaceutical Co., Ltd. is a high-tech enterprise engaged in the production and operation of APIs. The company has nearly a thousand employees, with more than 500 technical and management personnel with college degrees or above. The annual sales revenue is 600 million yuan, and its products are exported to more than 40 countries and regions in Europe and the United States, with an annual export value of 50 million US dollars. Since its establishment, the company has adhered to "improving good products and cultivating high realms," developing from bulk APIs such as Analgin, Metronidazole, and Chloramphenicol to characteristic APIs. The main product series include: Tirofiban Hydrochloride, Norepinephrine Bitartrate, Epinephrine, Enoxacin, Methoxyamine Hydrochloride, Chloroquine Sulfate, Pyrilamine Maleate, Glipizide, and other characteristic APIs and pharmaceutical intermediates. Among them, Enoxacin was the first Class II new drug after the promulgation of China's Drug Administration Law, Tirofiban Hydrochloride is a national "Torch Program" project, and Pyrilamine Maleate and Norepinephrine Bitartrate series products are exclusively produced nationwide. With the vision of "becoming a pharmaceutical company respected by Chinese doctors and patients, and giving back to society," the enterprise adheres to the core values of "providing good products and cultivating high realms." Its products cover APIs and raw material intermediates. The enterprise follows the development direction of product operation, adhering to "characteristic APIs in ophthalmology, cardiovascular, anti-infective, antipyretic and analgesic, and liver protection categories." To become a first-class pharmaceutical enterprise, a responsible pharmaceutical enterprise respected by doctors and patients, and a world-renowned supplier of characteristic APIs. With its profound historical accumulation, Wuyao Pharmaceutical has long been designated as a national strategic reserve enterprise for emergency medicines and narcotics. Several of its products, such as dimercaprol, have been rated as "conscientious drugs" and "trustworthy drugs" by the industry. In the next 5 years, the company will build a first-class domestic API industry chain by building new characteristic APIs and biopharmaceuticals, become a world-renowned supplier of characteristic APIs, and make new contributions to the health and well-being of the people.